TriSalus Life Sciences (TLSI) EPS (Weighted Average and Diluted) (2021 - 2026)

TriSalus Life Sciences has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at $0.03 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 107.69% year-over-year to $0.03; the trailing twelve-month figure through Mar 2026 stood at -$1.32 (down 17.86% YoY), and the FY2025 full-year result was -$1.84, down 40.46% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.03, up from -$0.12 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $0.09 in Q1 2022, with the low at -$79.38 in Q4 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged -$8.58 across 5 years, with a median of -$0.39 in 2025.
• The largest YoY upside for EPS (Weighted Average and Diluted) was 1000.0% in 2022 against a maximum downside of 88300.0% in 2022.
• TriSalus Life Sciences' EPS (Weighted Average and Diluted) stood at -$79.38 in 2022, then soared by 98.68% to -$1.05 in 2023, then surged by 61.9% to -$0.4 in 2024, then soared by 70.0% to -$0.12 in 2025, then surged by 125.0% to $0.03 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.03 (Q1 2026), -$0.12 (Q4 2025), and -$0.96 (Q3 2025), per Business Quant data.